Chemoresistance, Cancer Stem Cells, and MiRNA Influences: the Case for Neuroblastoma

Overview

Journal Anal Cell Pathol (Amst)

Specialties Cell Biology
Oncology
Pathology

Date 2015 Aug 11

PMID 26258008

Citations 24

Authors

Alfred Buhagiar

Duncan Ayers

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is a type of cancer that develops most often in infants and children under the age of five years. Neuroblastoma originates within the peripheral sympathetic ganglia, with 30% of the cases developing within the adrenal medulla, although it can also occur within other regions of the body such as nerve tissue in the spinal cord, neck, chest, abdomen, and pelvis. MicroRNAs (miRNAs) regulate cellular pathways, differentiation, apoptosis, and stem cell maintenance. Such miRNAs regulate genes involved in cellular processes. Consequently, they are implicated in the regulation of a spectrum of signaling pathways within the cell. In essence, the role of miRNAs in the development of cancer is of utmost importance for the understanding of dysfunctional cellular pathways that lead to the conversion of normal cells into cancer cells. This review focuses on highlighting the recent, important implications of miRNAs within the context of neuroblastoma basic research efforts, particularly concerning miRNA influences on cancer stem cell pathology and chemoresistance pathology for this condition, together with development of translational medicine approaches for novel diagnostic tools and therapies for this neuroblastoma.

Citing Articles

Extracellular vesicles in neuroblastoma: role in progression, resistance to therapy and diagnostics.

Dhamdhere M, Spiegelman V Front Immunol. 2024; 15:1385875.

PMID: 38660306 PMC: 11041043. DOI: 10.3389/fimmu.2024.1385875.

Development and validation of a novel stemness-related prognostic model for neuroblastoma using integrated machine learning and bioinformatics analyses.

Xia Y, Wang C, Li X, Gao M, Hogg H, Tunthanathip T Transl Pediatr. 2024; 13(1):91-109.

PMID: 38323183 PMC: 10839279. DOI: 10.21037/tp-23-582.

Therapy resistance in neuroblastoma: Mechanisms and reversal strategies.

Zhou X, Wang X, Li N, Guo Y, Yang X, Lei Y Front Pharmacol. 2023; 14:1114295.

PMID: 36874032 PMC: 9978534. DOI: 10.3389/fphar.2023.1114295.

SNHG25 facilitates SNORA50C accumulation to stabilize HDAC1 in neuroblastoma cells.

Zeng H, Pan J, Hu C, Yang J, Li J, Tan T Cell Death Dis. 2022; 13(7):597.

PMID: 35821006 PMC: 9276775. DOI: 10.1038/s41419-022-05040-z.

Mechanisms involved in selecting and maintaining neuroblastoma cancer stem cell populations, and perspectives for therapeutic targeting.

Farina A, Cappabianca L, Zelli V, Sebastiano M, Mackay A World J Stem Cells. 2021; 13(7):685-736.

PMID: 34367474 PMC: 8316860. DOI: 10.4252/wjsc.v13.i7.685.

References

Vaupel P, Mayer A . Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol. 2005; 12(1):5-10. DOI: 10.1016/j.tracli.2004.11.005. View

Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli M, Degli Uberti E . miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol. 2005; 204(1):280-5. DOI: 10.1002/jcp.20282. View

Rebucci M, Michiels C . Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013; 85(9):1219-26. DOI: 10.1016/j.bcp.2013.02.017. View

Borst P . Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?. Open Biol. 2012; 2(5):120066. PMC: 3376736. DOI: 10.1098/rsob.120066. View

Maris J . Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. PMC: 3306838. DOI: 10.1056/NEJMra0804577. View

Loven J, Zinin N, Wahlstrom T, Muller I, Brodin P, Fredlund E . MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci U S A. 2010; 107(4):1553-8. PMC: 2824410. DOI: 10.1073/pnas.0913517107. View

Blower P, Chung J, Verducci J, Lin S, Park J, Dai Z . MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008; 7(1):1-9. DOI: 10.1158/1535-7163.MCT-07-0573. View

Laneve P, Di Marcotullio L, Gioia U, Fiori M, Ferretti E, Gulino A . The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci U S A. 2007; 104(19):7957-62. PMC: 1876554. DOI: 10.1073/pnas.0700071104. View

Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V . Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol. 2014; 5:56. PMC: 3921882. DOI: 10.3389/fimmu.2014.00056. View

10.

Zuccotti P, Colombrita C, Moncini S, Barbieri A, Lunghi M, Gelfi C . hnRNPA2/B1 and nELAV proteins bind to a specific U-rich element in CDK5R1 3'-UTR and oppositely regulate its expression. Biochim Biophys Acta. 2014; 1839(6):506-16. DOI: 10.1016/j.bbagrm.2014.04.018. View

11.

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

12.

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

13.

Abedini M, Muller E, Bergeron R, Gray D, Tsang B . Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene. 2009; 29(1):11-25. DOI: 10.1038/onc.2009.300. View

14.

Wang X, Cao L, Wang Y, Wang X, Liu N, You Y . Regulation of let-7 and its target oncogenes (Review). Oncol Lett. 2012; 3(5):955-960. PMC: 3389667. DOI: 10.3892/ol.2012.609. View

15.

Ischenko I, Seeliger H, Schaffer M, Jauch K, Bruns C . Cancer stem cells: how can we target them?. Curr Med Chem. 2008; 15(30):3171-84. DOI: 10.2174/092986708786848541. View

16.

Yu Z, Pestell T, Lisanti M, Pestell R . Cancer stem cells. Int J Biochem Cell Biol. 2012; 44(12):2144-51. PMC: 3496019. DOI: 10.1016/j.biocel.2012.08.022. View

17.

Nagaraja A, Creighton C, Yu Z, Zhu H, Gunaratne P, Reid J . A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010; 24(2):447-63. PMC: 2817607. DOI: 10.1210/me.2009-0295. View

18.

Gillet J, Gottesman M . Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2009; 596:47-76. DOI: 10.1007/978-1-60761-416-6_4. View

19.

Qiao J, Lee S, Paul P, Theiss L, Tiao J, Qiao L . miR-335 and miR-363 regulation of neuroblastoma tumorigenesis and metastasis. Surgery. 2013; 154(2):226-33. PMC: 4165591. DOI: 10.1016/j.surg.2013.04.005. View

20.

Chen Y, Takita J, Choi Y, Kato M, Ohira M, Sanada M . Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008; 455(7215):971-4. DOI: 10.1038/nature07399. View